SPC280
Risankizúmab
Status:
VeittApplication date:
17.10.2019Application published:
15.11.2019Grant published:
15.11.2020
Max expiry date:
29.4.2034Medicine name:
SkyriziMedicine for children:
No
Timeline
Today
17.10.2019Application
15.11.2019Publication
15.11.2020Registration
29.4.2034Expires
Marketing license
IS authorization number:
EU/1/19/1361/001Date:
4.6.2019
Foreign authorization number:
EU/1/19/1361Date:
26.4.2019
Owner
Name:
Boehringer Ingelheim International GmbHAddress:
Binger Strasse 173, Ingelheim am Rhein DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2635601